Statins for the Early Treatment of Sepsis

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Sepsis

In brief

We propose a Phase II, randomized, placebo-controlled clinical trial to test the hypothesis that treatment with once-daily statins has a beneficial effect on inflammatory cytokines and clinical outcomes in adults hospitalized with sepsis. As our animal models suggest pretreatment with statins are required for their beneficial effects, we propose a study design intended to identify patients and initiate treatment early in their hospital stay. This Phase II study is intended to assess the feasibility of conducting a large-scale investigator-initiated translational research protocol that involves multiple clinical services within the Department of Medicine.

Key facts

Study ID

NCT00528580

Run by

University of Chicago

People needed

68

Starts

2008-02-01

Expected to finish

2011-09-01

Last updated by the study team

2018-09-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18 years
• Initial presentation to the Emergency Department or University of Chicago MD office/Dialysis Center for current hospital admission
• Sepsis (ACCP/SCCM criteria)
• Clinically suspected infection as per the treating physician or confirmed infection
• 2 or more of the following: Temperature 38ºC (100.4ºF)or 36ºC (96.8ºF), Heart rate (HR) > 90/min, Respiratory rate (RR) > 20/min or PaCO2 < 32 mmHg, White blood cell count > 12,000/mm3 or < 4000/m3 or > 10%immature neutrophils
• Initiation of antibiotics by treating physician for sepsis
• Hospitalized from the Emergency Department or University of Chicago MD office/Dialysis Center to an inpatient medical service (intensive care unit (ICU)or non-ICU service) OR admission to the medical ICU (MICU) from a non-ICU inpatient medical floor.
• Assent of the primary treating physician at the time of enrollment.
• The meeting of SIRS criteria is due to an infection as per the treating physician.

You may not qualify if…

• Pregnancy
• ALT >3 times above the upper limit of normal
• Elevated creatine phosphokinase (CPK) (>3 times the upper limit of normal)
• Concurrent treatment with any of the following drugs: daptomycin, fenofibrate, ketoconazole,triaconazole, amiodarone, clarithromycin, cyclosporine, erythromycin,nefazodone, niacin, protease inhibitors, telithromycin, verapamil,danazol, gemfibrozil
• History of allergy or intolerance to statins
• Greater than 16 hours after meeting inclusion criteria
• Use of 1 more doses of statins in the previous 4 weeks
• Clinical indication for treatment with statin during hospital admission (per treating physician)
• Sufficiently poor prognosis prior to enrollment that treating physicians have elected to employ comfort care or plan to discharge to hospice
• Transfer from surgical service to medical service
• Needing transfusion for either active bleeding or severe hemolysis.

Where it is running

• The University of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.